|Bid||0.00 x 800|
|Ask||20.50 x 900|
|Day's Range||18.70 - 20.17|
|52 Week Range||14.13 - 56.85|
|Beta (3Y Monthly)||0.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Is AxoGen, Inc. (NASDAQ:AXGN) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Alachua, Florida-based company said it had a loss of 24 cents. Losses, adjusted for stock option expense and non-recurring costs, were 15 cents per share. The results did not ...
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How far off is AxoGen, Inc. (NASDAQ:AXGN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to toda...
AxoGen, Inc.'s (NASDAQ:AXGN) announced its latest earnings update in December 2018, which suggested company earnings became less negative compared to the previous year's level as a result of recent tailwindsRead More...
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
Karen Zaderej became the CEO of AxoGen, Inc. (NASDAQ:AXGN) in 2011. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap Read More...
Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]
To receive further updates on this AxoGen Inc. (NASDAQ:AXGN) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today. After falling below support in the $31-$32 range last Monday, AXGN found a secondary support level near $27 on Tuesday, which held and sparked a three-day rally that took shares right back up to $31.
A medical technology company eyeing a $10 million project in Vandalia is seeking grant funding from Montgomery County. AxoGen, a Florida-based developer of nerve regeneration and repair technologies, has requested a $350,000 Economic Development/Government Equity grant from the county. The city of Vandalia recently submitted an application on behalf of the company, and the committee that determines which projects will receive funding will vote on the request Dec. 7.
AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Alachua, Florida-based company said it had a loss of 11 cents. Losses, adjusted for stock option expense, came to 5 cents per share. The results met Wall Street expectations. ...